Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05585021
Other study ID # 22-SM-08-WL-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 19, 2022
Est. completion date April 30, 2023

Study information

Verified date November 2023
Source Shenzhen Precision Health Food Technology Co. Ltd.,
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled trial, to evaluate the effect of WONDERLAB Probiotic Compound Powder on improving immunity of preschool children


Description:

The community hospital will recruit 140 preschool children, aged 5 to 6 years old, according to the inclusion and exclusion criteria, and randomly assigned them to 2 groups. 70 subjects in the placebo group and 70 in the experimental product group. First entered a one-week washout period, and then entered a 25-week clinical intervention, and finally ensured that 100 volunteers completed the whole study, and the withdrawal rate was about 28%.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 5 Years to 6 Years
Eligibility Inclusion Criteria: - Preschool children, male or female, 5 to 6 years old; - Those with weak constitution and easy to get sick: One of them can be satisfied: AGet cold = 3 times a year B Bronchitis or pneumonia =2 times per year C Rotavirus diarrhea =1 time per year - During the trial, participants agree not to take any drugs, supplements, or other dairy products containing probiotics; - During the trial, participants agree not to take any other prebiotic/bacterial drugs, supplements, or dairy products including yogurt drinks; - Willing to refrain from participating in other interventional clinical studies during the trial period; - Be able to fully understand the nature, purpose, benefits and possible risks and side effects of the research; - Willing to obey all test requirements and procedures; - Informed consent signed by parents or legal guardians. Exclusion Criteria: - Subject who is in the treatment of gastrointestinal diseases; - Subject who has lactose intolerance; - The subjects are currently suffering from other organic diseases that affect intestinal function, such as history of gastrointestinal resection, colonic or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.; - Subjects have any of the following medical histories or clinically diagnosed diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases; - According to the judgment of the researchers, frequent use of drugs that may affect gastrointestinal function or the immune system; - Subjects who took laxatives or other digestive aids 2 weeks before the start of the study; - Consumed dairy products or other foods containing prebiotics/bacteria within 10 days before the start of the study; - PI believes that volunteers cannot fully cooperate with the trial arrangement.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Wonderlab Kids instant probiotics
During study intervention, subjects are required to take the randomly assigned product based on the randomization list. Taking assigned product directly or mix it with milk/water/other liquids below 37 ?, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period.
Instant probiotic placebo
Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list. Taking assigned product directly or mix it with milk/water/other liquids below 37 ?, half an hour after meal. 1 bottle a day. Lasting for 24 weeks intervention period.

Locations

Country Name City State
China Wenan Wang Jinhua Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen Precision Health Food Technology Co. Ltd.,

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rotavirus diarrhea Testing at baseline Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 12 month baseline(day 0)
Primary Rotavirus diarrhea Testing at endpoint Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 168 days endpoint( day 168)
Primary Infection of the upper respiratory tract at baseline Drug records of upper respiratory tract infection within past 12 months. baseline(day 0)
Primary Infection of the upper respiratory tract at endpoint Drug records of upper respiratory tract infection within past 168 days. endpoint ( day 168)
Secondary Bristol Stool Chart To evaluate samples of human feces based on the shape and consistency of the stool. baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)
Secondary Faeces sIgA ?16sRNA?SCFA?Fecal calprotectin baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)
Secondary Saliva sIgA testing baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175)
Secondary Pittsburgh sleep quality index 18 items comprise 7 components, each of which is scored according to o~3 grade. The cumulative score of each component is the total score of PSQI, with a total score range of 0~2l. The higher the score, the worse the sleep quality. baseline(day 0)/interim ( day 84)/endpoint( day 168)
See also
  Status Clinical Trial Phase
Completed NCT02814617 - The Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity Phase 2/Phase 3
Completed NCT02244372 - Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity N/A
Completed NCT00990002 - Investigation of A Children's Beverage Containing Different Probiotics N/A
Completed NCT00788021 - Protective Immunity Project 01 N/A
Completed NCT01736787 - Efficacy and Safety of Cauliflower Mushroom Extract on Promotion of Immunity N/A
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Completed NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine N/A
Completed NCT05162820 - Impact of Solarplast® on Immunity in Active Smokers and Non-smokers N/A
Completed NCT01657656 - Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia N/A
Recruiting NCT05117385 - The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune) N/A
Completed NCT05190237 - the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement. N/A
Completed NCT04647071 - Allium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers N/A
Completed NCT04031222 - Mechanisms of Inflammation, Immunity, Islet Cell and Intestinal Hormone Changes in Youth at Risk for Diabetes
Completed NCT04010331 - Efficacy and Safety of Nokyong Mixture Extract(CME-PI) on Promotion of Immunity N/A
Completed NCT03067714 - A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy Phase 3
Completed NCT04664309 - Understanding Immunity to the COVID-19 Vaccines
Withdrawn NCT06121362 - Effect of Protocatechuic Acid on Biochemical Markers of Immunity Status in Healthy Adults N/A
Recruiting NCT02166931 - BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition N/A
Recruiting NCT00645996 - The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants N/A
Completed NCT03336086 - Effect of Weight Reduction on Immunity Phase 3